Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Interventional Radiology Market Size & Share 2026-2035
Report ID: GMI3576
|
Published Date: September 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Jump to Content
Market Size
Market Trends
Market Analysis
Market Share
Market Companies
Industry News
Frequently Asked Questions
Research Methodology
Related Reports
Download Free PDF
Interventional Radiology Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Interventional Radiology Market Size
The global interventional radiology market was valued at USD 30.9 billion in 2025 and is projected to reach USD 51.5 billion by 2035, expanding at a 5.2% CAGR. Growth reflects the increasing use of image-guided techniques to diagnose and treat vascular, oncologic, and organ-specific conditions while limiting the tissue disruption associated with open procedures.
Interventional Radiology Market Key Takeaways
Market Leader: Koninklijke Philips led with over 22% market share in 2025.
Leading Players: Top 5 players in this market include Canon Medical Systems, Fujifilm Corporation, GE Healthcare, Koninklijke Philips, Siemens Healthineers, which collectively held a market share of 58% in 2025.
Disease burden provides a durable demand base across the market's largest clinical pathways. Cardiovascular diseases caused an estimated 19.8 million deaths worldwide in 2022, sustaining demand for angiography-led diagnosis and catheter-based vascular intervention [1]. Cancer added an estimated 20 million new cases and 9.7 million deaths in 2022, supporting use of image-guided biopsy, ablation, and embolization in diagnostic and therapeutic pathways [2]. These are not interchangeable demand pools: cardiovascular care favors real-time vascular visualization and device-intensive procedures, whereas oncology increasingly requires precise targeting, treatment monitoring, and multidisciplinary coordination.
Technology investment is shifting from stand-alone imaging acquisition toward procedural ecosystems. AI research in interventional radiology includes real-time anatomical recognition, automated ablation-path planning, and predictive models for treatment response, although many applications remain at an early clinical-development stage [3]. Robotic platforms can improve catheter control and reduce operator exposure to ionizing radiation, but their adoption depends on proof of workflow fit, capital availability, and trained operators rather than on imaging performance alone [4]. Hybrid suites and radiation-free MRI-guided intervention therefore represent both a growth opportunity and a capital-allocation decision for providers.
GMI Analyst View
The market's expansion is anchored in clinical demand that cannot be met through imaging alone: cardiovascular and cancer burdens create recurring need for procedures that combine visualization, navigation, and therapy. The commercial consequence is that equipment suppliers compete increasingly on the completeness of the intervention workflow, including planning, guidance, dose management, devices, training, and service support, rather than on scanner specifications in isolation.
Technology is widening the addressable procedural set, but it also raises the threshold for adoption. AI-enabled guidance, robotics, and hybrid-room configurations can increase precision and help manage radiation exposure; however, their economic value is realized only where procedure volumes, multidisciplinary staffing, and infrastructure utilization justify the investment. Demand will therefore remain strongest where clinical complexity and utilization can support integrated image-guided care.
Key Drivers
Chronic cardiovascular and cancer care requirements support procedure demand across multiple equipment categories. Cardiovascular disease creates need for vascular visualization, revascularization, and embolization procedures, while oncology raises utilization of image-guided biopsy and localized tumor treatment. The 19.8 million cardiovascular deaths recorded in 2022 and the 20 million new cancer cases recorded in the same year indicate that interventional radiology demand is being supported by large, clinically distinct patient populations rather than by a single therapeutic indication.
Advances in imaging are improving the feasibility of technically complex interventions. AI applications under development include automated trajectory planning for radiofrequency ablation and predictive procedural models, while robotic systems can support more stable device control and reduce hand tremor during catheter-based procedures. These capabilities matter commercially because they may improve reproducibility in procedures that are otherwise dependent on specialist experience. They also increase the importance of interoperable software, workflow integration, and clinical training.
Investment in image-guided infrastructure is creating a higher-value equipment opportunity. GE HealthCare and MediView announced the first clinical installation of an augmented-reality interventional suite in Minneapolis in June 2024, illustrating how advanced visualization is being brought into procedural settings rather than confined to diagnostic departments [5]. Facilities considering hybrid operating rooms must assess utilization across vascular, oncologic, and surgical service lines; a suite used by only one specialty may struggle to justify its capital intensity.
Radiation management is becoming a design and procurement consideration, not merely a safety compliance issue. In a study of angiographic interventions, real-time visual dosimetry reduced mean operator dose by 36% and assisting-staff dose by 30% [6]. A 2025 joint CIRSE and SIR guideline supports radiation-safety programs and real-time dosimetry practices for interventional radiology personnel [7]. These requirements favor imaging and workflow configurations that can document exposure and make dose management visible during procedures.
Demand for minimally invasive treatment is reinforced by the ability to move selected diagnostic and therapeutic procedures from large inpatient pathways toward outpatient-capable settings. The resulting value proposition depends on clinical appropriateness, referral networks, imaging access, and recovery protocols. It is therefore most relevant to providers that can combine procedural efficiency with escalation pathways for complex cases.
Key Restraints
The cost of advanced imaging platforms extends beyond initial equipment acquisition. Hospitals must also fund room construction, shielding, software integration, disposable devices, maintenance, applications support, and training. This creates a material barrier for providers with limited procedure volumes and makes capital sales sensitive to the ability to share a system across cardiology, oncology, surgery, and radiology. The constraint is especially acute for hybrid configurations, where the economics depend on room utilization rather than on imaging demand alone.
Regulatory complexity slows the conversion of technical capability into routine clinical use. AI-enabled guidance, robotic controls, and connected imaging workflows introduce requirements around validation, software lifecycle management, cybersecurity, clinical evidence, and post-market monitoring. The 2025 CIRSE/SIR occupational-protection guideline also illustrates that procedural imaging is subject to an evolving professional standard for radiation safety, documentation, and workplace protection. Manufacturers that can pair innovation with implementation support are better positioned than those offering isolated hardware features.
GMI Analyst View
The principal constraint is not a lack of clinical need; it is the uneven ability of providers to absorb the full cost and operating model of advanced intervention. Capital-intensive systems become more attractive when they support several specialties, reduce workflow friction, and sustain a high enough procedural throughput to spread fixed costs. This favors vendors that can design modular upgrade paths and demonstrate value beyond image quality.
Regulatory and safety requirements reinforce that advantage. As AI, robotics, and dose-management features become more embedded in procedural workflows, suppliers must establish evidence, integration reliability, and service capabilities alongside technical differentiation. The market can grow steadily while adoption of the most advanced platforms remains concentrated in institutions capable of managing these clinical and operational dependencies.
Interventional Radiology Market Segment Analysis
By Product
Angiography systems accounted for a 21.5% market share in 2025 and are projected to reach approximately USD 10.6 billion by 2035, advancing at an estimated 4.7% CAGR. Their leading position reflects their central role in vascular imaging and catheter-based intervention. The segment's growth is durable but comparatively measured because installed-base replacement cycles and room-level capital requirements temper adoption.
Ultrasound imaging systems are projected to record the fastest product growth, at approximately 6.1% CAGR. Ultrasound-guided vascular access, biopsy, drainage, and ablation can expand procedural access without requiring ionizing radiation, which gives the modality a practical advantage in outpatient-oriented and resource-constrained settings. Its growth potential is strengthened when fusion imaging and AI-assisted image acquisition improve confidence in technically demanding interventions.
CT scanners generated approximately USD 5.1 billion in 2025. Their value in interventional radiology lies in high-resolution targeting for deep lesions, biopsies, drain placements, and ablation planning. MRI systems generated approximately USD 4.6 billion in 2025 and are positioned where soft-tissue characterization and radiation-free guidance can justify longer procedure times and specialized infrastructure. The Siemens Healthineers and Cook Medical iMRI Suite, announced in 2025, combines real-time MRI with MRI-specific interventional devices, demonstrating a pathway for radiation-free intervention rather than a direct substitute for conventional angiography [8].
Fluoroscopy systems remain integral to real-time procedural visualization, while biopsy devices support a broad set of diagnostic pathways. Other products include specialized accessories and guidance technologies that can benefit from broader adoption of image-guided treatment, though their demand is typically linked to the installed base of imaging platforms.
By Application
Cardiology represented 31.4% of market revenue in 2025. The segment benefits from the scale of cardiovascular disease and the dependence of vascular procedures on real-time imaging, device navigation, and intraprocedural assessment. Its commercial profile favors integrated angiography, intravascular imaging, and catheter-based device ecosystems rather than stand-alone imaging purchases.
Oncology is projected to expand at the fastest application CAGR of approximately 5.9%. The global cancer burden supports increasing use of image-guided biopsy and localized interventions, particularly where ablation and embolization can complement surgical, systemic, or radiation-oncology pathways. Growth depends on multidisciplinary referral models and the availability of imaging that can define targets accurately and monitor treatment response.
Gynecology, obstetrics, urology, and gastroenterology provide additional procedure demand through condition-specific interventions. Their contribution varies by local care protocols, specialist availability, and whether the institution can coordinate imaging access with procedural scheduling. Other applications broaden the market's exposure to neurological, musculoskeletal, and organ-specific interventions.
By End Use
Hospitals held a 50.7% share of revenue in 2025. Complex vascular and oncologic interventions require multidisciplinary staff, emergency support, anesthesia coverage, and access to multiple imaging modalities, making hospitals the principal setting for high-acuity procedures. Their ability to deploy a platform across several departments also improves the economics of advanced capital equipment.
Clinics accounted for approximately USD 7.8 billion in 2025. Their role is expanding where lower-acuity procedures can be delivered through focused referral, imaging, intervention, and follow-up pathways. Clinics may reduce patient waiting times and hospital burden, but their product requirements differ from those of tertiary hospitals: footprint, workflow speed, service availability, and escalation arrangements can be as important as maximum procedural complexity.
Ambulatory surgical centers can support selected image-guided procedures when reimbursement, staffing, and patient-selection practices align. Other end-use settings remain relevant for decentralized access, but their adoption is constrained by the need for specialized operators, imaging infrastructure, and clinical governance.
GMI Analyst View
Segment growth will not be uniform because each modality solves a different procedural problem. Angiography retains its central position in vascular intervention, but ultrasound's higher projected growth reflects its ability to support lower-radiation, flexible, and potentially outpatient-oriented workflows. CT and MRI are more selective investments: they command value where lesion targeting, soft-tissue visualization, or radiation avoidance changes clinical management.
The same divergence applies across end users. Hospitals remain the core market because they can manage complex cases and spread imaging assets across departments. Clinics and ambulatory settings expand the addressable market only where care pathways can safely separate lower-acuity interventions from inpatient infrastructure. Suppliers that match modality configuration, service design, and training to each site-of-care model are likely to capture more value than those relying on a uniform capital-equipment proposition.
Interventional Radiology Market Regional Analysis
North America
North America generated USD 11.1 billion in 2025 and is projected to reach USD 17.2 billion by 2035, representing a 4.40% CAGR. Its approximately 36% global share in 2025 reflects a large installed base of advanced imaging, established interventional programs, and strong concentration of medical-technology suppliers. The United States accounted for USD 10.5 billion in 2025 and is projected to reach USD 16.1 billion by 2035, while Canada is expected to increase from USD 665.8 million to USD 1.1 billion over the same period.
The region's growth is increasingly tied to the modernization of procedural workflows. The 2024 clinical installation of GE HealthCare and MediView's augmented-reality interventional suite demonstrates demand for technologies that combine visualization with procedural navigation. Adoption will be shaped by provider ability to integrate these systems into established imaging, operating-room, and outpatient networks.
Europe
Europe was valued at USD 7.8 billion in 2025 and is projected to reach USD 12.6 billion by 2035. Mature health systems and an extensive hospital base support continued equipment replacement and procedural expansion, although country-level procurement and regulatory pathways remain heterogeneous.
Germany is a significant regional center for image-guided intervention. DeGIR registry analyses document nationwide provision of radiologically guided tumor interventions and interventional revascularization procedures, indicating the availability of organized procedural capacity across oncology and vascular care. The German opportunity is therefore linked not only to equipment demand but also to systems capable of supporting standardized workflows in established clinical networks. The UK, France, Spain, Italy, and the Netherlands contribute through developed hospital infrastructure and demand for minimally invasive care, although their adoption pace varies with local capital budgets and care-delivery models.
Asia Pacific
The Asia Pacific region generated USD 9.2 billion in 2025 and is forecast to reach USD 16.9 billion by 2035, making it the region with the largest projected revenue increase over the forecast period. The opportunity combines a large patient base with expanding access to hospital care and image-guided treatment, but adoption remains uneven between advanced urban centers and lower-resource settings.
China's Healthy China 2030 strategy emphasizes expanded healthcare access, primary care, and health equity, creating a policy environment that can support broader diagnostic and treatment capacity. Japan, Australia, and South Korea have established imaging infrastructure and can support earlier use of advanced procedural technology. In India, Ayushman Bharat PM-JAY provides eligible beneficiaries with hospitalization coverage of up to INR 5 lakh per family annually and targets approximately 550 million beneficiaries across 12 crore families [9]. Broader financial access can improve the addressable population for tertiary procedures, but local provider capacity and specialist availability remain decisive.
Medical-tourism hubs add a separate demand channel. Malaysia's medical-tourism industry generated USD 444 million in 2023, while private hospitals increasingly market specialized care to regional patients. Thailand and Malaysia also promote hospitals with interventional-radiology capability, supporting cross-border demand for cardiology and oncology-related procedures.
Latin America
Latin America was valued at USD 1.7 billion in 2025 and is projected to reach USD 3.1 billion by 2035. Brazil is the region's key market, supported by a broad range of interventional practice spanning vascular procedures, image-guided biopsy, tumor ablation, embolization, and drainage interventions. A hybrid angiography-CT suite at Real Hospital Português de Recife illustrates how advanced capacity is being established for vascular, oncologic, neurologic, and stroke interventions.
Mexico and Argentina expand the regional opportunity, but capital availability, uneven access to specialized care, and public-private differences in infrastructure can slow the replacement of conventional systems with integrated intervention suites. Vendors must balance advanced clinical functionality with financing, local service capacity, and sustainable ownership costs.
Middle East & Africa
The Middle East & Africa market was valued at USD 978.0 million in 2025 and is projected to reach USD 1.7 billion by 2035. Growth is concentrated in markets with healthcare investment and specialist hospital development, while access remains fragmented across the broader region.
Saudi Arabia is a focal point for advanced interventional capacity. King Faisal Specialist Hospital & Research Centre identifies interventional radiology and fluoroscopy, non-vascular neuro-interventions, and musculoskeletal imaging and intervention among its service capabilities. In April 2025, the institution reported an endovascular treatment for limb-threatening arterial disease, demonstrating the operational use of non-surgical vascular intervention. The Saudi Interventional Radiology Society also provides a professional platform for training and practice development. South Africa and the UAE contribute through specialist care centers, though provider concentration and capital intensity remain material constraints.
GMI Analyst View
Regional growth is increasingly differentiated by the way each healthcare system funds and organizes procedural care. North America and Western Europe offer installed-base replacement, advanced workflow upgrades, and high-acuity intervention demand. Asia Pacific provides a larger expansion runway, but suppliers must accommodate substantial variation in reimbursement, training, infrastructure, and provider purchasing power.
Emerging markets are not simply lower-cost versions of mature markets. India's coverage expansion may increase access to tertiary care, China's health-policy direction supports capacity development, and medical-tourism hubs can concentrate demand in private centers. In Latin America and the Middle East, leading institutions can adopt hybrid and specialized systems before surrounding markets do. This produces a two-track commercial environment: high-end reference sites require integrated solutions, while broader penetration depends on adaptable configurations, financing, and local clinical support.
Interventional Radiology Market Share & Competitive Landscape
The competitive environment includes Agfa-Gevaert Group, Canon Medical Systems, Carestream Health Inc., Cook, Esaote SPA, Fujifilm Corporation, GE Healthcare, Hologic Inc., Koninklijke Philips, Mindray, Olympus Corporation, Samsung Healthcare, Shimadzu Corporation, Siemens Healthineers, and Teleflex.
Competition is shaped by the ability to combine imaging platforms, procedural devices, software, applications expertise, and field service. Broad imaging vendors, including Canon Medical Systems, Fujifilm Corporation, GE Healthcare, Koninklijke Philips, Samsung Healthcare, Shimadzu Corporation, and Siemens Healthineers, compete through modality breadth and integration with hospital imaging ecosystems. Companies such as Cook, Teleflex, Hologic Inc., and Olympus Corporation participate through procedure-focused device and specialty portfolios. Agfa-Gevaert Group, Carestream Health Inc., Esaote SPA, and Mindray contribute through imaging, informatics, and modality-specific propositions that can be relevant to different provider budgets and clinical workflows.
The competitive basis is moving toward interoperability and procedural usability. AI-guided planning, robotic navigation, radiation monitoring, and cloud-enabled imaging create differentiation only when they reduce friction for clinicians and fit existing hospital systems. This places emphasis on implementation capability, clinical training, maintenance response, and lifecycle support alongside product performance.
Koninklijke Philips, Canon Medical Systems, and GE Healthcare are positioned in the advanced imaging and workflow segment, where enterprise integration and clinical applications support complex hospital purchasing decisions. Siemens Healthineers and Cook demonstrate the importance of collaboration between imaging and intervention-device specialists through their radiation-free iMRI suite partnership. Teleflex's acquisition of substantially all of BIOTRONIK's Vascular Intervention business expands its position in coronary and peripheral vascular devices, strengthening the role of procedure-specific portfolios in a market otherwise led by broad imaging ecosystems.
Recent Industry Developments
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Question(FAQ) :
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →